Organon (OGN) Income towards Parent Company (2020 - 2026)
Organon (OGN) recorded quarterly Income towards Parent Company of $146.0 million in Q1 2026, up 171.22% quarter-over-quarter from -$205.0 million in Q4 2025, and up 67.82% on a YoY basis from $87.0 million in Q1 2025.
Organon (OGN) Income towards Parent Company (2020 - 2026) Analysis & Trends
Organon's Income towards Parent Company history runs 6 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 67.82% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $246.0 million (down 67.2% YoY), while the FY2025 annual figure was $187.0 million, down 78.36% from the prior year.
- Income towards Parent Company was $146.0 million for Q1 2026 at Organon, up from -$205.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $546.0 million in Q4 2023 to a low of -$205.0 million in Q4 2025.
- Historically, Income towards Parent Company has averaged $170.8 million across 4 years, with a median of $160.0 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 518.97% in 2024, then sank 288.07% in 2025.
- A 4-year view of Income towards Parent Company shows it stood at $546.0 million in 2023, then plunged by 80.04% to $109.0 million in 2024, then tumbled by 288.07% to -$205.0 million in 2025, then jumped by 171.22% to $146.0 million in 2026.
- The last three Income towards Parent Company figures came in at $146.0 million (Q1 2026), -$205.0 million (Q4 2025), and $160.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,162,528.78 Bn | 93,162,523.82 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.87 Bn | 1,012.58 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 575.51 Bn | 553.46 Bn | 15.96 Bn |
| 4 | AbbVie | 400.43 Bn | 391.08 Bn | 10.78 Bn |
| 5 | Merck | 294.19 Bn | 288.54 Bn | 12.09 Bn |
| 6 | Amgen | 182.41 Bn | 170.37 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 150.97 Bn | 143.24 Bn | 5.52 Bn |
| 8 | Pfizer | 145.75 Bn | 132.97 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.35 Bn | 102.90 Bn | 8.07 Bn |
| 10 | Organon | 3.48 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | -205.00 Mn |
| Sep 30, 2025 | 160.00 Mn |
| Jun 30, 2025 | 145.00 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 109.00 Mn |
| Sep 30, 2024 | 359.00 Mn |
| Jun 30, 2024 | 195.00 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 546.00 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 242.00 Mn |
| Mar 31, 2023 | 177.00 Mn |
| Jun 30, 2021 | -4.00 Mn |
| Mar 31, 2021 | 4.00 Mn |
| Dec 31, 2020 | -8.00 Mn |
| Sep 30, 2020 | -13.00 Mn |
| Jun 30, 2020 | -44.00 Mn |
| Mar 31, 2020 | -31.00 Mn |